Literature DB >> 18829672

Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia.

I N Park1, Y Jegal, D S Kim, K-H Do, B Yoo, T S Shim, C-M Lim, S D Lee, Y Koh, W S Kim, W D Kim, S J Jang, M Kitaichi, A G Nicholson, T V Colby.   

Abstract

Most studies of idiopathic nonspecific interstitial pneumonia (NSIP) have primarily studied mortality. In order to clarify the detailed outcome and prognostic markers in idiopathic NSIP, the clinical course with initial radiological and clinical features was analysed. The clinical course of 83 patients who were classified with idiopathic NSIP (72 fibrotic, 11 cellular; 27 males and 56 females; mean+/-sd age 54.4+/-10.1 yrs) was retrospectively analysed. In fibrotic NSIP, 16 (22%) patients died of NSIP-related causes with a median (range) follow-up of 53 (0.3-181) months. Despite the favourable survival (5-yr 74%), patients with fibrotic NSIP were frequently hospitalised with recurrence rate of 36%. Reduced forced vital capacity at 12 months was a predictor of mortality. On follow-up, lung function was improved or stable in approximately 80% of the patients. The extent of consolidation and ground-glass opacity on initial high-resolution computed tomography correlated significantly with serial changes of lung function, and the presence of honeycombing was a predictor of poor prognosis. During follow-up, eight (10%) patients developed collagen vascular disease. In conclusion, the overall prognosis of fibrotic nonspecific interstitial pneumonia was good; however, there were significant recurrences despite initial improvement and a subset of the patients did not respond to therapy. Some patients developed collagen vascular diseases at a later date.

Entities:  

Mesh:

Year:  2008        PMID: 18829672     DOI: 10.1183/09031936.00158507

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  31 in total

1.  Diffuse interstitial lung disease: overlaps and uncertainties.

Authors:  Simon L F Walsh; David M Hansell
Journal:  Eur Radiol       Date:  2010-03-04       Impact factor: 5.315

2.  [Current classification of interstitial pulmonary diseases].

Authors:  J Vogel-Claussen; A Prasse
Journal:  Radiologe       Date:  2014-12       Impact factor: 0.635

3.  Cyclosporin A in idiopathic chronic fibrosing interstitial pneumonia without idiopathic pulmonary fibrosis.

Authors:  Reoto Takei; Machiko Arita; Fumiaki Tokioka; Hiromasa Tachibana; Hironobu Tokumasu; Tadashi Ishida
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

4.  Pulmonary Toxicities of Immunotherapy.

Authors:  Mehmet Altan; Linda Zhong; Vickie R Shannon; Ajay Sheshadri
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

Authors:  William D Travis; Ulrich Costabel; David M Hansell; Talmadge E King; David A Lynch; Andrew G Nicholson; Christopher J Ryerson; Jay H Ryu; Moisés Selman; Athol U Wells; Jurgen Behr; Demosthenes Bouros; Kevin K Brown; Thomas V Colby; Harold R Collard; Carlos Robalo Cordeiro; Vincent Cottin; Bruno Crestani; Marjolein Drent; Rosalind F Dudden; Jim Egan; Kevin Flaherty; Cory Hogaboam; Yoshikazu Inoue; Takeshi Johkoh; Dong Soon Kim; Masanori Kitaichi; James Loyd; Fernando J Martinez; Jeffrey Myers; Shandra Protzko; Ganesh Raghu; Luca Richeldi; Nicola Sverzellati; Jeffrey Swigris; Dominique Valeyre
Journal:  Am J Respir Crit Care Med       Date:  2013-09-15       Impact factor: 21.405

6.  Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia.

Authors:  Robert W Hallowell; Robert M Reed; Mostafa Fraig; Maureen R Horton; Reda E Girgis
Journal:  Pulm Circ       Date:  2012 Jan-Mar       Impact factor: 3.017

7.  Treatment response and long term follow-up results of nonspecific interstitial pneumonia.

Authors:  Ji Yeon Lee; Sang-Man Jin; Byoung Jun Lee; Doo Hyun Chung; Bo-Gun Jang; Heae Surng Park; Sang-Min Lee; Jae-Joon Yim; Seok-Chul Yang; Chul-Gyu Yoo; Sung Koo Han; Young-Soo Shim; Young Whan Kim
Journal:  J Korean Med Sci       Date:  2012-05-26       Impact factor: 2.153

8.  Diffuse alveolar damage: a common phenomenon in progressive interstitial lung disorders.

Authors:  Riitta Kaarteenaho; Vuokko L Kinnula
Journal:  Pulm Med       Date:  2010-11-02

9.  Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease.

Authors:  Tsutomu Hamada; Takuya Samukawa; Tomohiro Kumamoto; Kazuhito Hatanaka; Go Tsukuya; Masuki Yamamoto; Kentaro Machida; Masaki Watanabe; Keiko Mizuno; Ikkou Higashimoto; Yoshikazu Inoue; Hiromasa Inoue
Journal:  BMC Pulm Med       Date:  2015-09-30       Impact factor: 3.317

Review 10.  [Pulmonary manifestations in collagen vascular diseases].

Authors:  M N A Vogel; M Kreuter; H-U Kauczor; C-P Heußel
Journal:  Radiologe       Date:  2016-10       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.